Loading patent…
AssigneeIntralytix, Inc.
InventorsJ. Glenn Morris, Alexander Sulakvelidze, Zemphira Alavidze, Gary R. Pasternack, Torrey C. Brown
Estimating the term…
The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.
A method for reducing the risk of bacterial infection or sepsis in a person colonized with pathogenic bacteria comprising treating the colonized person with a pharmaceutical composition containing bacteriophage of one or more strains which produce lyric infections in said pathogenic bacteria, wherein said treatment occurs prior to said colonized person developing an illness due to said pathogenic bacteria and said treatment reduces the risk of bacterial infection or sepsis in said colonized person, and wherein said treatment of the colonized person reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log, wherein said composition is administered intravesicularly, topically, orally, rectally, ocularly, otically, nasally, or via inhalation.
A method for reducing the incidence of infection by selected pathogenic bacteria in a medical facility comprising administering to patients admitted to the medical facility a bacteriophage preparation which reduces the colonization level by the selected pathogenic bacteria in patients at risk for infection by the selected pathogenic bacteria, wherein said colonization level is reduced by at least one log, wherein said bacteriophage preparation is administered intravesiculady, topically, orally, rectally, ocularly, otically, nasally, or via inhalation.
A method for reducing the level of colonization in a patient comprising treating the patient with a composition containing bacteriophage of one or more strains which produce lyric infections in pathogenic bacteria, wherein said patient is colonized with the pathogenic bacteria subject to infection by said bacteriophage, and wherein said treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log, wherein said composition is administered intxavesicularly, topically, orally, rectally, ocularly, otically, nasally, or via inhalation.
Dependencies are inferred from the claim text.